Navigation Links
Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
Date:4/12/2011

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /PRNewswire/ -- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with thousands of patients successfully enrolled.  A 30,000 patient enrollment study across 1500 sites is currently in-process with four more in the pipeline.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Current Ph IV success and activities are due to a specific business model Max Neeman created for such 'Observational studies' based on over 10 years of experience. Segments of the business model include: zonal stratification of >1000 sites and SOPs to improve quality of patient data retrieved in large studies. More than 30 CSRs have been developed to date.

The prevalence of diabetes in India is only second to China with 50.8 million people diagnosed with the disease and expected to rise steeply in the coming years. More large Ph IV studies are predicted and Max Neeman is prepared with a Ph IV strategy that is a combination of operational excellence (via Six Sigma practices), dedicated and trained project management teams, flexible delivery models, a customized approach and integrated technology. All these combine to deliver positive results on a customer's objective in a swift and cost effective manner.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP
'/>"/>

SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Max Neeman Develops Innovative Approach for Rare Disease Studies
2. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
3. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
6. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
7. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
8. PRA International Experts to Speak at Drug Safety Conference
9. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
10. Mauna Kea Technologies Announces Highlights of Third International Conference of Cellvizio Users (ICCU)
11. Two New U.S. Patents Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Denver, Colorado (PRWEB) August 21, 2014 ... filled with celebrities making pleas for donations to fight ... funds will be well-known national companies and brands through ... the public’s, the 2013 MDA Telethon raised nearly $60 ... as Zinga Frozen Yogurt franchisees, cause-related marketing ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... 2014 The International Board ... an organization recognizing professionals dedicated to promoting quality ... that with a certificate in autism , ... the Autism Spectrum have a way to show ... This, in turn, say IBCCES representatives, increases the ...
(Date:8/20/2014)... 19, 2014 (HealthDay News) -- A group representing U.S. ... a flu shot. According to the American College ... recent years have upheld the safety and effectiveness of ... highly infectious and can be particularly dangerous to pregnant ... other complications," Dr. Laura Riley, chair of the college,s ...
(Date:8/20/2014)... that the immune system is defective in people suffering from ... have ongoing issues with pain. , The research the ... help to explain why some painkillers may not offer satisfactory ... to 10% of the community. There are different forms ... which often has the greatest impact on sufferers, quality of ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... on knees can also repair damaged ankles claim the ... repairing knee injuries, but it is also a valuable ... minimally invasive surgical technique it is being applied in ... problems, including ligament damage, bone chips and recurrent pain ...
... disease, is becoming an elite disease as so much of ... As a result of such ongoing research, hyperhomocysteinemia (increased levels ... the risk factors.// ,Dr. O Mayer Jr and colleagues ... result of their study that beer may provide enough folate--a ...
... pharmaceutical companies hope to strike a pot of gold ... price war that is likely to escalate in coming ... lured many companies to develop anti-AIDS drugs and market ... to pricing. ,The anti-AIDS drug market, currently dominated ...
... is injurious to health"- this warning , printed in every cigarette ... of smoking in many. But now the fact that even a ... by the researchers of North Carolina. ,It is a well ... the diseases such as heart attack , cancer etc.,. ...
... little as 10 minutes of moderate exercise daily can improve mood ... fact that exercise has its benefit towars the physical asset. But ... as to how much exercise will benefit. This is based on ... bicycle for longer periods and did not find any benefits as ...
... and ulcerative colitis, often grouped together under inflammatory ... industrialized nations with stringent standards of public hygiene. ... human immune system from interacting with worms, bacteria ... properly...Yes! Doctors at the University of Iowa are ...
Cached Medicine News:Health News:Arthroscopy for Ankles 2Health News:WORM! WORM! all the way 2
... This type of anchor is generally utilized when ... directly into the bone. Unlike other anchors that ... anchor does not have that limitation. The only ... is a mallet. The 4.4mm Stainless Steel Anchor ...
... Yasushi Nakao, M.D., Smith & Nephew ... flexor,tendon release for fingers and thumbs ... approach is designed to decrease patient ... of releasing the A1 pulley under ...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: